Kailera Therapeutics (NASDAQ:KLRA) Trading 6.6% Higher - Here's Why

Key Points

• Kailera Therapeutics shares rose 6.6% to $19.13 in Monday trading, with volume of about 341,212 shares—51% below the average session volume.
• Analyst coverage was broadly positive, with a consensus “Buy” rating and an average price target of $42.75; Jefferies set the highest target at $48.
• The company reported quarterly EPS of -$1.09, missing the consensus estimate of -$0.74, while analysts expect a full-year loss of about $3.63 per share.

Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA - Get Free Report) were up 6.6% during trading on Monday . The stock traded as high as $19.21 and last traded at $19.13. Approximately 341,212 shares were traded during mid-day trading, a decline of 51% from the average session volume of 700,079 shares. The stock had previously closed at $17.94.

Analyst Ratings Changes

KLRA has been the topic of a number of analyst reports. Jefferies Financial Group began coverage on Kailera Therapeutics in a research report on Tuesday, May 12th. They issued a "buy" rating and a $48.00 price target on the stock. Leerink Partners initiated coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They set an "outperform" rating and a $36.00 price objective for the company. William Blair began coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They issued an "outperform" rating on the stock. Evercore assumed coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They issued an "outperform" rating on the stock. Finally, Zacks Research upgraded shares of Kailera Therapeutics to a "hold" rating in a research report on Wednesday, May 13th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $42.75.

Kailera Therapeutics Price Performance

The firm has a market cap of $2.48 billion and a price-to-earnings ratio of -0.01. The stock has a 50-day moving average of $19.43.

Kailera Therapeutics (NASDAQ:KLRA - Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($1.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.35). Sell-side analysts anticipate that Kailera Therapeutics, Inc. will post -3.63 EPS for the current fiscal year.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source